Rafferty Asset Management
RPTX

Rafferty Asset Management’s Repare Therapeutics RPTX Stock Holding History

Rafferty Asset Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67,759
Closed -$948K – 1234
2022
Q2 		$948K Buy
+67,759
New +$798K 0.01% 665

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rafferty Asset Management's RPTX Position: Q3 2022 in Review

Rafferty Asset Management sold out of Repare Therapeutics (RPTX) in Q3 2022, closing a stake of 67,759 shares — an estimated $948K sold.

Rafferty Asset Management first reported a position in RPTX in Q2 2022 and held it in 1 quarter. The position peaked at $948K in Q2 2022. 71 funds tracked by Wall St. Rank hold RPTX as of Q3 2022.

  • Rafferty Asset Management reported no remaining Repare Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 67,759 Repare Therapeutics shares in Q3 2022, an estimated $948K.
  • Rafferty Asset Management first reported a position in Repare Therapeutics in Q2 2022 and held it in 1 quarter.
  • Rafferty Asset Management's Repare Therapeutics position peaked at $948K in Q2 2022.
  • 71 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2022.

Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.